Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

Similar articles for PubMed (Select 20068274)

1.

[Pathophysiology and treatment of paroxysmal nocturnal hemoglobinuria (PNH)--recent advances].

Shichishima A, Shichishima T; Study Group of Tohoku Hematology Forum.

Rinsho Ketsueki. 2009 Dec;50(12):1679-86. Review. Japanese. No abstract available.

PMID:
20068274
2.
3.

Bone marrow failure syndromes: paroxysmal nocturnal hemoglobinuria.

Parker CJ.

Hematol Oncol Clin North Am. 2009 Apr;23(2):333-46. doi: 10.1016/j.hoc.2009.01.014. Review.

PMID:
19327587
4.

New insights into paroxysmal nocturnal hemoglobinuria.

Savage WJ, Brodsky RA.

Hematology. 2007 Oct;12(5):371-6. Review.

PMID:
17852463
5.
6.

Eculizumab: A novel therapy for paroxysmal nocturnal hemoglobinuria.

Zareba KM.

Drugs Today (Barc). 2007 Aug;43(8):539-46. Review.

PMID:
17925885
7.

Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.

Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, Cullen MJ, Richards SJ, Rollins SA, Mojcik CF, Rother RP.

N Engl J Med. 2004 Feb 5;350(6):552-9.

8.

Which patients with paroxysmal nocturnal hemoglobinuria (PNH) should be treated with eculizumab? ASH evidence-based review 2008.

Haspel RL, Hillmen P.

Hematology Am Soc Hematol Educ Program. 2008:35. doi: 10.1182/asheducation-2008.1.35. No abstract available.

9.

[Eculizumab in paroxysmal nocturnal hemoglobinuria].

SociƩ G, Varoqueaux N, Peffault de Latour R.

Med Sci (Paris). 2009 Dec;25(12):1126-9. doi: 10.1051/medsci/200925121126. Review. French.

10.

Update on eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.

Hill A.

Clin Adv Hematol Oncol. 2008 Jul;6(7):499-500. Review. No abstract available.

PMID:
18654116
11.

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.

Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L.

Nat Biotechnol. 2007 Nov;25(11):1256-64. Erratum in: Nat Biotechnol. 2007 Dec;25(12):1488.

PMID:
17989688
12.
13.

Eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.

Hill A.

Clin Adv Hematol Oncol. 2005 Nov;3(11):849-50. No abstract available.

PMID:
16491626
14.

Paroxysmal nocturnal hemoglobinuria.

Parker CJ.

Curr Opin Hematol. 2012 May;19(3):141-8. doi: 10.1097/MOH.0b013e328351c348. Review.

PMID:
22395662
15.

New insights into paroxysmal nocturnal hemoglobinuria.

Brodsky RA.

Hematology Am Soc Hematol Educ Program. 2006:24-8, 516. Review.

16.

The role of complement inhibition in PNH.

Hillmen P.

Hematology Am Soc Hematol Educ Program. 2008:116-23. doi: 10.1182/asheducation-2008.1.116.

17.

Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria.

Hill A, Richards SJ, Hillmen P.

Br J Haematol. 2007 May;137(3):181-92. Review.

PMID:
17408457
18.

New insights into molecular pathogenesis of bone marrow failure in paroxysmal nocturnal hemoglobinuria.

Kawaguchi T, Nakakuma H.

Int J Hematol. 2007 Jul;86(1):27-32. Review.

PMID:
17675263
19.

Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumab.

Singer AL, Locke JE, Stewart ZA, Lonze BE, Hamilton JP, Scudiere JR, Anders RA, Rother RP, Brodsky RA, Cameron AM.

Liver Transpl. 2009 May;15(5):540-3. doi: 10.1002/lt.21714.

20.

Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.

Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, Kawaguchi T, Nakao S, Nakakuma H, Nishimura J, Kinoshita T, Bedrosian CL, Valentine ME, Khursigara G, Ozawa K, Omine M.

Int J Hematol. 2011 Jan;93(1):36-46. doi: 10.1007/s12185-010-0748-9. Epub 2011 Jan 12.

PMID:
21222185
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk